Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients

Kirkpantur, Alper; Balci, Mustafa; Gurbuz, Oguz; Afsar, Barış; Canbakan, Basol; Akdemir, Ramazan; Ayli, Mehmet

doi:10.1093/ndt/gfq539

Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients

Kirkpantur A., Balci M., Gurbuz O. A., Afsar B., Canbakan B., Akdemir R., ...Daha Fazla

NEPHROLOGY DIALYSIS TRANSPLANTATION, cilt.26, sa.4, ss.1346-1354, 2011 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 26 Sayı: 4
Basım Tarihi: 2011
Doi Numarası: 10.1093/ndt/gfq539
Dergi Adı: NEPHROLOGY DIALYSIS TRANSPLANTATION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1346-1354
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Süleyman Demirel Üniversitesi Adresli: Evet

Özet

Background. Fibroblast growth factor-23 (FGF-23) is a phosphorus-regulating substance. Circulating FGF-23 levels increase markedly in dialysis patients and are independently associated with increased risk of mortality. Given the fact that cardiovascular disease is the leading cause of death in dialysis patients, the aim of this study was to test if elevated FGF-23 levels might be associated with left ventricular mass index (LVMI) and left ventricular index of myocardial performance (MPI) in maintenance haemodialysis patients.